NCT00204659View on ClinicalTrials.gov

Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Primary Gastric Diffuse-Large B-Cell Lymphoma
Interventions
DRUG

Rituximab + CHOP chemotherapy

standard Rituximab + CHOP chemo-immunotherapy

Trial Locations (5)

35392

University of Giessen, Giessen

72076

University of Tubingen, Tübingen

78050

Schwarzwald-Baar Clinic, Villingen-Schwenningen

86156

Zentralklinikum Augsburg, Augsburg

Unknown

Klinikum Reutlingen, Reutlingen

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University Hospital Tuebingen

OTHER

NCT00204659 - Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter